AbbVie Inc. (ABBV) — closed signal from October 18, 2025
Partial Published before the outcome was known, scored automatically when the window closed on January 16, 2026.
Predicted vs. what happened
What happened
Reached 35% of the predicted growth at its peak, without hitting the target.
The thesis — published October 18, 2025
AbbVie looks beaten down after heavy selling, which can set up a short-term snapback. Buying the depression drug bretisilocin adds a new option to its pipeline. Still, a possible patent fight and leadership shifts create noise. A 3-month rebound is possible if the price settles and investors keep favoring steady, defensive healthcare stocks. Because the story has open questions, a smaller position makes sense.
Primary drivers
- Shares fell hard recently, but investor mood remains fairly positive.
- New drug added through a purchase, giving the research pipeline a boost.
- Healthcare often holds up in uncertain markets, which can aid the stock.
- Possible patent dispute and leadership changes could unsettle results.
How it played out
ABBV: target was not reached
On 2025-10-18, Lyra published a short-term ABBV rebound thesis at $229.57. It expected 12% growth toward $257.12. The thesis pointed to heavy recent selling, a possible snapback, a new depression drug added through a purchase, support from defensive healthcare demand, and risks from a possible patent dispute and leadership changes.
Inside the window from 2025-10-18 to 2026-01-16, ABBV peaked at $239.29 on 2025-11-13, a 4.2% gain. It stayed below the $257.12 target. It ended at $214.35. The thesis partially played out early, but the target was missed.
What happened during the window
On 2025-10-31, Investor's Business Daily reported AbbVie's third-quarter results, including $15.78 billion in revenue and adjusted earnings of $1.86 per share. On 2026-01-13, The Wall Street Journal reported that AbbVie had struck a deal with the Trump administration to invest $100 billion in U.S. operations and lower Medicaid prices.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.